2m 2m 2m 2m 2m 2m 2m
INHIBIKASE THRP (IKT)
NASDAQ
$2.18-$0.005 (-0.23%)
Price as of Jul 31, 2026 7:58 PM EDT- $342.3MMarket Cap
- 43.42%1-Year Change
- BiotechnologyIndustry
INHIBIKASE THRP (IKT)
$2.18-$0.005 (-0.23%)
IKT | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $2.18 | ||
Change | -$0.10 (-4.39%) | ||
Open | $2.27 | ||
High | $2.29 | ||
Low | $2.13 | ||
Previous Close | $2.28 | ||
Volume | 369,382 | ||
30-Day Average Volume | 990,779 | ||
1-Week Change | -6.44% | ||
1-Month Change | 7.39% | ||
1-Year Change | 43.42% | ||
3-Year Change | -13.49% | ||
5-Year Change | -83.99% | ||
Fundamentals | |||
Shares Outstanding | 157.0M | ||
Total Assets | $173.3M | ||
Market Cap | $342.3M | ||
Enterprise Value | $292.8M | ||
Period: QTR TTM FY | |||
Revenue | $1.5M | ||
Net Income | -$16.4M | ||
Free Cash Flow | -$12.1M | ||
EBIT | -$16.4M | ||
EBITDA | -$16.4M | ||
Net Working Capital | $166.5M | ||
EPS | -$0.10 | ||
Enterprise Value/EBITDA | -18 | ||
Enterprise Value/Revenue | 200 | ||
P/B | 2 | ||
P/E | -22 | ||
PEG | -7 | ||
Price/Free Cash Flow | -28 | ||
Price/Operating Cash Flow | -28 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | 1 : 6 | ||
Last Split Date | 06/30/2023 | ||
Earnings & Revenue